PDCD1 and neoplasm: As one of the representatives of immunotherapy, programmed cell death protein 1 (PD-1) antibodies can inactivate tumor cells’ checkpoint and unleash cytotoxic T cells’ anti-tumor effects, but still major patients do not show complete responses (13).